NewAmsterdam Pharma Company N.V./$NAMS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Ticker
$NAMS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
77
Website
NAMS Metrics
BasicAdvanced
$2.6B
-
-$1.85
-0.03
-
Price and volume
Market cap
$2.6B
Beta
-0.03
52-week high
$26.95
52-week low
$14.06
Average daily volume
913K
Financial strength
Current ratio
19.977
Quick ratio
19.8
Long term debt to equity
0.018
Total debt to equity
0.05
Profitability
EBITDA (TTM)
-189.582
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-397.45%
Operating margin (TTM)
-402.49%
Effective tax rate (TTM)
0.00%
Revenue per employee (TTM)
$610,000
Management effectiveness
Return on assets (TTM)
-18.15%
Return on equity (TTM)
-31.51%
Valuation
Price to revenue (TTM)
50.712
Price to book
3.41
Price to tangible book (TTM)
3.41
Price to free cash flow (TTM)
-16.986
Free cash flow yield (TTM)
-5.89%
Free cash flow per share (TTM)
-138.93%
Growth
Revenue change (TTM)
586.97%
Earnings per share change (TTM)
-32.18%
3-year revenue growth (CAGR)
-2.29%
3-year earnings per share growth (CAGR)
110.07%
Bulls say / Bears say
NewAmsterdam Pharma's lead drug, obicetrapib, has demonstrated positive results in Phase 3 trials, significantly reducing LDL-C levels in patients with cardiovascular diseases, indicating strong potential for regulatory approval and market adoption. (Seeking Alpha)
The company maintains a robust financial position with approximately $808 million in cash and no debt, providing ample resources to support ongoing research and development activities. (Simply Wall St)
Analysts have set an average 12-month price target of $42.89 for NAMS, suggesting a potential upside of over 100% from the current stock price. (MarketBeat)
In Q1 2025, NewAmsterdam Pharma reported a loss of $0.49 per share, missing the consensus estimate of a $0.45 loss, indicating potential challenges in achieving profitability. (Nasdaq)
Analysts have recently reduced their revenue forecasts for the company by 14%, reflecting concerns about future sales performance. (Simply Wall St)
Despite positive trial results, the company faces competition from established cholesterol-lowering therapies, which may impact obicetrapib's market penetration and revenue potential. (Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NewAmsterdam Pharma Company N.V. stock?
NewAmsterdam Pharma Company N.V. (NAMS) has a market cap of $2.6B as of July 28, 2025.
What is the P/E ratio for NewAmsterdam Pharma Company N.V. stock?
The price to earnings (P/E) ratio for NewAmsterdam Pharma Company N.V. (NAMS) stock is 0 as of July 28, 2025.
Does NewAmsterdam Pharma Company N.V. stock pay dividends?
No, NewAmsterdam Pharma Company N.V. (NAMS) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next NewAmsterdam Pharma Company N.V. dividend payment date?
NewAmsterdam Pharma Company N.V. (NAMS) stock does not pay dividends to its shareholders.
What is the beta indicator for NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. (NAMS) has a beta rating of -0.03. This means that it has an inverse relation to market volatility.